Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223269 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HTTCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL25447805 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HTTCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL1140476 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HTTCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL21455835 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HTTCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL7246527 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HTTCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL1106510 | 0.97 | CHRNB2 (0.46) | ALDH1A1HTTCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL4546653 | 0.92 | — | — | |
| SCHEMBL22753493 | 0.86 | CHRNB2 (0.50) | ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL4546617 | 0.86 | CHRNB2 (0.50) | ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL674660 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-03-09 | — | — | US | disclosed |
| US-10961256-B2 | PRMT5 inhibitors | CTXT PTY LTD (AU) | 2021-03-30 | — | — | US | disclosed |
| EP-3189042-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-03-17 | — | — | EP | disclosed |
| US-10766863-B2 | Monocarboxylate transport modulators and uses thereof | NIROGYONE THERAPEUTICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10752610-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-10669258-B2 | 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2020-02-04 | — | — | US | disclosed |
| WO-2019243851-A1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-12-26 | — | — | WO | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2009073713-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | NEUROGEN CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | NEUROGEN CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-7326709-B2 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | ALDH1A1 809/4885HTT 382/4885CHRNB2 373/4885 |
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | GABBR1, GABBR2, GABRA4 | ALDH1A1 1142/4885HTT 2776/4885CHRNB2 108/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | ALDH1A1 3412/4885HTT 1751/4885CHRNB2 1046/4885 |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | ALDH1A1 372/4885HTT 4589/4885CHRNB2 4733/4885 |
| US-10766863-B2 | Monocarboxylate transport modulators and uses thereof | SLC16A1, SLC16A3, SLC16A7 | ALDH1A1 521/4885HTT 1880/4885CHRNB2 4644/4885 |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | PTK6, NEK6, GRK6 | ALDH1A1 4782/4885HTT 1508/4885CHRNB2 4326/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | ALDH1A1 1999/4885HTT 2641/4885CHRNB2 659/4885 |
| US-10961256-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ALDH1A1 4022/4885HTT 2139/4885CHRNB2 2501/4885 |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ALDH1A1 4296/4885HTT 1632/4885CHRNB2 2526/4885 |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | CYP3A4, CYP4A22, HCCS | ALDH1A1 858/4885HTT 4539/4885CHRNB2 4867/4885 |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | PREP, HCCS, PEPD | ALDH1A1 2140/4885HTT 3278/4885CHRNB2 4867/4885 |
| US-10669258-B2 | 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonists | AP3D1, KCNJ5, TBXA2R | ALDH1A1 899/4885HTT 4234/4885CHRNB2 405/4885 |
| US-10752610-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | ALDH1A1 1597/4885HTT 1912/4885CHRNB2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.